{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:11:15Z","timestamp":1768439475287,"version":"3.49.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing periodic updates on new and anticipated novel drug approvals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Selected drug approvals anticipated in the 12-month period covering the first quarter of 2024 through the fourth quarter of 2024 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 59 novel drugs awaiting US Food and Drug Administration approval. This year\u2019s pipeline includes recently added drugs with various indications including oncology, infectious diseases, genetic disorders, and rare diseases. New cellular and gene therapies are rapidly evolving and being studied for several rare diseases and cancers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>More oncology agents, including gene therapies, oral agents, and monoclonal antibodies, are in the pipeline this year. Additional diseases targeted by new novel drugs, including cellular and gene therapies, are hemophilia, nonalcoholic steatohepatitis, Alzheimer\u2019s disease, and rare diseases such as galactosemia and epidermolysis bullosa.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae046","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T18:21:17Z","timestamp":1708366877000},"page":"385-389","source":"Crossref","is-referenced-by-count":5,"title":["Recent and anticipated novel drug approvals for 2024"],"prefix":"10.1093","volume":"81","author":[{"given":"Matthew H","family":"Rim","sequence":"first","affiliation":[{"name":"Northwestern Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany L","family":"Karas","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Barada","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M","family":"Levitsky","sequence":"additional","affiliation":[{"name":"IPD Analytics , Aventura, FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"2024050710564810700_CIT0001","year":"2024"},{"key":"2024050710564810700_CIT0002","doi-asserted-by":"crossref","DOI":"10.1093\/ajhp\/zxad220","article-title":"Recent and anticipated novel drug approvals for 2023 and 2024","author":"Rim","year":"2023","journal-title":"Am J Health-Syst Pharm"},{"key":"2024050710564810700_CIT0003","author":"US Food and Drug Administration"},{"key":"2024050710564810700_CIT0004","author":"US Food and Drug Administration"},{"key":"2024050710564810700_CIT0005","author":"OncLive"},{"key":"2024050710564810700_CIT0006","author":"Aldeyra Therapeutics"},{"key":"2024050710564810700_CIT0007","author":"Merck","year":"2023"},{"issue":"16 suppl","key":"2024050710564810700_CIT0008","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1200\/JCO.2023.41.16_suppl.11563","article-title":"The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): analysis of overall survival in advanced synovial sarcoma","volume":"41","author":"Brian Andrew Van Tine","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024050710564810700_CIT0009","author":"BeiGene"},{"issue":"26","key":"2024050710564810700_CIT0010","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non\u2013small-cell lung cancer: Results from LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"2024050710564810700_CIT0011","doi-asserted-by":"crossref","first-page":"TPS8611","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8611","article-title":"Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304)","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024050710564810700_CIT0012","doi-asserted-by":"crossref","first-page":"1912885","DOI":"10.1080\/2162402X.2021.1912885","article-title":"Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with bacillus Calmette-Gu\u00e9rin (BCG) for the treatment of bladder cancer","volume":"10","author":"Rosser","year":"2021","journal-title":"Oncoimmunology"},{"key":"2024050710564810700_CIT0013","author":"National Cancer Institute","year":"2023"},{"key":"2024050710564810700_CIT0014","author":"Regeneron Pharmaceuticals Inc","year":"2023"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae046\/56994672\/zxae046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/10\/385\/57435538\/zxae046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/10\/385\/57435538\/zxae046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T10:57:04Z","timestamp":1715079424000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/81\/10\/385\/7610734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":14,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,2,19]]},"published-print":{"date-parts":[[2024,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae046","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,15]]},"published":{"date-parts":[[2024,2,19]]}}}